AVROBIO
Avrobio is a clinical stage company developing step-change cell and gene therapies targeting cancer and rare disease. The catalyst for creating Avrobio is to accelerate scientific breakthroughs related to the convergence of cell and gene therapies. The patient’s own cells can be effectively modified to deliver novel genes to cure serious debilitating disease. Avrobio was founded by industry leaders with unmatched scientific, business, and manufacturing expertise in the field of cell and gene therapy.
AVROBIO
Industry:
Biotechnology Genetics Health Care
Founded:
2015-01-01
Address:
Cambridge, Massachusetts, United States
Country:
United States
Website Url:
http://www.avrobio.com
Total Employee:
101+
Status:
Active
Contact:
(617) 914 8420
Email Addresses:
[email protected]
Total Funding:
85 M USD
Technology used in webpage:
IPv6 Akamai Hosted
Similar Organizations
Electra Therapeutics
Electra Therapeutics is a clinical stage biotechnology company developing therapies for cancer and other immunological diseases.
Stemline Therapeutics
Stemline Therapeutics is a clinical stage biopharmaceutical company developing oncology compounds that target cancer stem cells.
Current Advisors List
Current Employees Featured
Founder
Stock Details
Investors List
Morningside Venture Partners
Morningside Venture Partners investment in Series B - Avrobio
Citadel
Citadel investment in Series B - Avrobio
Clarus Ventures
Clarus Ventures investment in Series B - Avrobio
Leerink Partners
Leerink Partners investment in Series B - Avrobio
Aisling Capital
Aisling Capital investment in Series B - Avrobio
Brace Pharma
Brace Pharma investment in Series B - Avrobio
SV Health Investors
SV Health Investors investment in Series B - Avrobio
Eventide
Eventide investment in Series B - Avrobio
Atlas Venture
Atlas Venture investment in Series B - Avrobio
Cormorant Asset Management
Cormorant Asset Management investment in Series B - Avrobio
Key Employee Changes
Official Site Inspections
http://www.avrobio.com Semrush global rank: 3.6 M Semrush visits lastest month: 3.58 K
- Host name: 187.81.197.104.bc.googleusercontent.com
- IP address: 104.197.81.187
- Location: United States
- Latitude: 38.6583
- Longitude: -77.2481
- Timezone: America/New_York
More informations about "Avrobio"
Avrobio - Crunchbase Company Profile & Funding
Avrobio is a clinical stage company developing step-change cell and gene therapies targeting cancer and rare disease. The catalyst for creating Avrobio …See details»
Tectonic Therapeutic - Homepage - Tectonic Therapeutic
Tectonic and AVROBIO have completed their anticipated merger. Please follow this link to our press release for additional information. About Us. Tectonic is a clinical stage biotechnology company focused on the discovery and development of therapeutic proteins and antibodies …See details»
AVROBIO and Tectonic Therapeutic Announce Merger
About the Proposed Transaction: Financials, Management and Organization Upon completion of the Merger, pre-Merger AVROBIO shareholders are expected to own approximately 22.3% of the combined company and pre-Merger Tectonic shareholders are expected to own approximately …See details»
Tectonic Therapeutic Announces Closing of Merger with AVROBIO …
Jun 20, 2024 Following the reverse stock split and based on the final exchange ratio of approximately 0.5344 shares of AVROBIO common stock for each share of Tectonic common stock, at the closing of the merger ...See details»
AVROBIO - LinkedIn
AVROBIO Biotechnology Research Cambridge, Massachusetts 18,033 followers Clinical-stage lentiviral gene therapy company, powered by plato®.See details»
AVROBIO Company Profile 2024: Valuation, Investors, Acquisition
AVROBIO General Information Description. Developer of lentiviral-based gene therapies designed to halt or reverse Lysosomal disorders with a single dose. The company is engaged in developing potentially curative ex vivo lentiviral gene therapies to treat rare diseases following a single …See details»
AVROBIO, Inc. - AnnualReports.com
AVROBIO, Inc. vision is to bring personalized gene therapy to the world. They aim to halt or reverse disease throughout the body by driving durable expression of functional protein, even in hard-to-reach tissues and organs including the brain, muscle and bone.See details»
Avrobio - Funding, Financials, Valuation & Investors - Crunchbase
Avrobio is a clinical stage company developing step-change cell and gene therapies targeting cancer and rare disease. Search Crunchbase. Start Free Trial . ... How much funding has this organization raised over time? Show . Announced Date . Transaction Name . Number of …See details»
Avrobio’s road ends in reverse merger with Tim Springer-backed …
Jan 31, 2024 Dive Insight: The transaction gives Tectonic a path to go public while salvaging some value for Avrobio stockholders, who have seen the value of their shares drop to just over $1 from $19 at the time of the company’s 2018 initial public offering.. After stopping work on one …See details»
Novartis to buy Avrobio gene therapy for $88M, ending M&A rumor
May 22, 2023 Once the $87.5 million lands in its bank, Avrobio estimates it will have the money to fund operations into the fourth quarter of next year. A global registrational phase 2/3 clinical trial of ...See details»
Avrobio halts gene therapy research and considers a sale
Jul 12, 2023 Dive Brief: Gene therapy developer Avrobio on Wednesday said it will stop further development of its experimental medicines and explore alternative business options, such as a sale.; As a result of the change in direction, Avrobio will reduce its workforce by 50%. …See details»
AVROBIO Announces Leadership Transition - Business Wire
May 1, 2023 AVROBIO, Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company working to free people from a lifetime of genetic disease, today announcedSee details»
Novartis buys rare disease gene therapy from Avrobio
May 22, 2023 Gene therapy developer Avrobio will sell one of its three clinical-stage treatments to Novartis for $87.5 million, swapping an asset for cash it will use to extend its operating runway by at least another six months. The deal, announced by Avrobio Monday, will hand Novartis a …See details»
AVROBIO Announces Agreement to Sell Cystinosis Gene
May 22, 2023 About AVROBIO Our vision is to bring personalized gene therapy to the world. We target the root cause of genetic disease by introducing a functional copy of the affected gene into patients’ own ...See details»
AVROBIO and Tectonic Therapeutic Announce Merger - Yahoo …
Jan 30, 2024 CAMBRIDGE, Mass. & WATERTOWN, Mass., January 30, 2024--AVROBIO, Inc. (Nasdaq: AVRO) and Tectonic Therapeutic, Inc. ("Tectonic"), a privately-held biotechnology company developing GPCR (G-protein ...See details»
Avrobio hopes to get investors back on gene therapy bandwagon
Dec 7, 2022 Avrobio will host an update on the Gaucher program Wednesday at 8 a.m. ET. The company's shares were trading up just under 6% in pre-market trading to 89 cents, compared to a prior close of 84 cents.See details»
AVROBIO Announces New Positive Clinical Data and Preclinical …
Nov 17, 2020 AVROBIO explicitly disclaims any obligation to update any forward-looking statements except to the extent required by law. 1 Collaborator-sponsored Phase 1/2 clinical trial of AVR-RD-04 is funded ...See details»
AVROBIO and Tectonic Therapeutic Announce Merger - Nasdaq
Jan 30, 2024 CAMBRIDGE, Mass.& WATERTOWN, Mass.---- AVROBIO, Inc. and Tectonic Therapeutic, Inc., a privately-held biotechnology company developing GPCR- targeted therapeutic proteins, co-founded by Timothy A ...See details»
AVROBIO Announces Positive Data from Phase 1/2 Clinical Trial of ...
May 18, 2023 AVROBIO explicitly disclaims any obligation to update any forward-looking statements except to the extent required by law. _____ 1 The collaborator-sponsored Phase 1/2 clinical trial for ...See details»
AVROBIO Provides Regulatory Update on Investigational AVR-RD-01
May 3, 2021 AVROBIO explicitly disclaims any obligation to update any forward-looking statements except to the extent required by law. 1 Fabrazyme® (agalsidase beta) is a registered trademark owned by Sanofi ...See details»